Compare · NVO vs PBLA
NVO vs PBLA
Side-by-side comparison of Novo Nordisk A/S (NVO) and Panbela Therapeutics Inc. (PBLA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and PBLA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $167.46B.
- NVO has hit the wire 9 times in the past 4 weeks while PBLA has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 1 for PBLA).
- Company
- Novo Nordisk A/S
- Panbela Therapeutics Inc.
- Price
- -
- -
- Market cap
- $167.46B
- -
- 1M return
- -4.16%
- -
- 1Y return
- -20.63%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 9
- 0
- Recent ratings
- 25
- 1
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Panbela Therapeutics Inc.
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer. Its lead product candidate is SBP-101, which is in Phase 1a/1b clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was founded in 2011 and is based in Waconia, Minnesota.
Latest NVO
- Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest PBLA
- Panbela Therapeutics Inc. filed SEC Form 8-K: Leadership Update
- Panbela Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Panbela Therapeutics Inc. filed SEC Form 8-K: Events That Accelerate or Increase a Direct Financial Obligation, Changes in Control of Registrant
- SEC Form S-8 filed by Panbela Therapeutics Inc.
- SEC Form 4 filed by Large owner Nant Capital, Llc
- SEC Form 424B3 filed by Panbela Therapeutics Inc.
- SEC Form 424B3 filed by Panbela Therapeutics Inc.
- SEC Form 424B3 filed by Panbela Therapeutics Inc.
- SEC Form 424B3 filed by Panbela Therapeutics Inc.
- SEC Form 424B3 filed by Panbela Therapeutics Inc.